Matches in Nanopublications for { <http://bio2rdf.org/drugbank:DB05505> ?p ?o ?g. }
Showing items 1 to 12 of
12
with 100 items per page.
- drugbank:DB05505 type drugbank_vocabulary:Drug assertion.
- drugbank:DB05505 label "NM-702 [drugbank:DB05505]" assertion.
- drugbank:DB05505 seeAlso DB05505 assertion.
- drugbank:DB05505 description "Nissan Chemical and Taisho have been jointly developing NM-702, a drug for the treatment of arteriosclerosis obliterans. M-702 is an orally active inhibitor of phosphodiesterase and thromboxane synthetase. In Japan, Phase 2 studies are being conducted for intermittent claudication caused by arteriosclerosis obliterans, intermittent claudication caused by spinal canal stenosis, and asthma. In the USA, a Phase 2 study for intermittent claudication caused by arteriosclerosis obliterans has been successfully completed. Intermittent claudication is a major symptom of arteriosclerosis obliterans. It is caused by insufficient oxygen supply to exercising muscles in the lower extremities due to decreased blood flow as a result of sclerosis of peripheral arteries. It is estimated that about 6 million people suffer from intermittent claudication in the USA, with only 10 percent of these people currently receiving treatment. Patients with claudication experience significant disability, owing to their exercise limitation. Therapeutic options to improve exercise performance in these patients are limited" assertion.
- drugbank:DB05505 identifier "drugbank:DB05505" assertion.
- drugbank:DB05505 title "NM-702" assertion.
- drugbank:DB05505 drugbank_vocabulary:x-cas cas: assertion.
- drugbank:DB05505 drugbank_vocabulary:drugbank-id "DB05505" assertion.
- drugbank:DB05505 bio2rdf_vocabulary:x-identifiers.org DB05505 assertion.
- drugbank:DB05505 bio2rdf_vocabulary:uri "http://bio2rdf.org/drugbank:DB05505" assertion.
- drugbank:DB05505 bio2rdf_vocabulary:namespace "drugbank" assertion.
- drugbank:DB05505 bio2rdf_vocabulary:identifier "DB05505" assertion.